| Dopamine: the rewarding years. | |
| | |
MedLine Citation:
|
PMID: 16402097 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Dopamine has moved from being an insignificant intermediary in the formation of noradrenaline in 1957 to its present-day position as a major neurotransmitter in the brain. This neurotransmitter is involved in the control of movement and Parkinson's disease, the neurobiology and symptoms of schizophrenia and attention deficit hyperactivity disorder. It is also considered an essential element in the brain reward system and in the action of many drugs of abuse. This evolution reflects the ability of several famous names in neuropharmacology, neurology and psychiatry to apply new techniques to ask and answer the right questions. There is now excellent knowledge about the metabolism of dopamine, dopamine receptor systems and the structural organisation of dopamine pathways in the brain. Less is known about the function of the different receptors and how the various dopamine pathways are organised to produce normal behaviour, which exhibits disruption in the disease states mentioned. In particular, we have very limited information as to why and how the dopamine system dies or becomes abnormal in Parkinson's disease or a neurodevelopmental disorder such as schizophrenia. Dopamine neurones account for less than 1% of the total neuronal population of the brain, but have a profound effect on function. The future challenge is to understand how dopamine is involved in the integration of information to produce a relevant response rather than to study dopamine in isolation from other transmission systems. This integrated approach should lead to greater understanding and improved treatment of diseases involving dopamine. |
| | |
Authors:
|
Charles A Marsden |
Related Documents
:
|
10600547 - Involvement of ryanodine receptor type 3 in dopamine release from the striatum: evidenc... 15590157 - The non-peptidic delta opioid receptor agonist tan-67 enhances dopamine efflux in the n... 6121537 - Prejunctional inhibitory dopamine receptors in the rat isolated vas deferens. 1675147 - Differential effects of dopamine agonists upon stimulated limbic and striatal dopamine ... 18394247 - Criteria for basic tastes and other sensory primaries. 18438937 - Expression of the receptor for advanced glycation end products in oligodendrocytes in r... |
Publication Detail:
|
Type: Historical Article; Journal Article; Portraits |
Journal Detail:
|
Title: British journal of pharmacology Volume: 147 Suppl 1 ISSN: 0007-1188 ISO Abbreviation: Br. J. Pharmacol. Publication Date: 2006 Jan |
Date Detail:
|
Created Date: 2006-01-10 Completed Date: 2006-12-27 Revised Date: 2009-11-18 |
Medline Journal Info:
|
Nlm Unique ID: 7502536 Medline TA: Br J Pharmacol Country: England |
Other Details:
|
Languages: eng Pagination: S136-44 Citation Subset: IM |
Affiliation:
|
School of Biomedical Sciences, Institute of Neuroscience, Medical School, Queen's Medical Centre, University of Nottingham, Nottingham NG7 2UH. Charles.marsden@nottingham.ac.uk |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Dopamine
/
history*,
physiology History, 20th Century History, 21st Century Humans Receptors, Dopamine / history*, physiology Schizophrenia / drug therapy, etiology, history Substance-Related Disorders / etiology, history |
| Chemical | |
Reg. No./Substance:
|
0/Receptors, Dopamine |
| Comments/Corrections | |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Histamine and its receptors.
Next Document: Neuropharmacology of 5-hydroxytryptamine.